Robert Barrow, MindMed CEO
April 14, 2023 09:57 AM EDT
R&D

MindMed gains af­ter in­ves­ti­ga­tor tri­al of LSD shows im­pact on ma­jor de­pres­sion

Drew Armstrong

Executive Editor

Shares of MindMed surged Fri­day morn­ing af­ter re­searchers who have worked with the com­pa­ny un­veiled pos­i­tive re­sults in a tri­al us­ing LSD to treat ma­jor …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times